Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Trevi Therapeutics advances Haduvio in chronic cough, overcomes financial hurdles

Trevi Therapeutics is progressing with Haduvio's development in chronic cough indications
Financially, the company is managing its resources prudently and eliminating debt
Challenges persist with study delays due to supply shortages, but opportunities for growth are evident

Trevi Therapeutics advances Haduvio trials amidst financial stability

Trevi Therapeutics' financials show resilience with a focus on clinical advancements.
Challenges in trial planning and FDA outcomes require strategic navigation.
Opportunities for growth lie in upcoming trials and conference participation.
Overall, Trevi Therapeutics is positioned for continued progress and innovation.

Trevi Therapeutics advances novel cough treatments amidst financial challenges

Trevi Therapeutics is advancing innovative treatments for refractory chronic cough. Despite financial challenges, the company's strong cash position and ongoing clinical trials position it well for future growth.

Trevi Therapeutics reports Q1 loss, progresses in clinical trials

Trevi Therapeutics faces challenges with timelines for top line data in ongoing trials but holds promise in clinical development.
The company's financial performance reflects increased R&D expenses but maintains a strong cash position for future growth.

Trevi Therapeutics reports Q2 loss, advances in key trials

Trevi Therapeutics' Q2 2024 performance reflects ongoing investment in research with a net loss of $12.4 million and R&D expenses at $10 million.
Management's strategic focus on IPF and RCC trials, along with new leadership appointments and study initiations, underpin the company's commitment to therapeutic advancements.
While facing challenges like enrollment imbalances and financial pressures, Trevi Therapeutics remains poised for growth with upcoming data readouts and a strong research pipeline.

Trevi Therapeutics reports Q3 loss, eyes upcoming milestones and trials

Trevi Therapeutics is navigating increased R&D expenses, with a strong cash position and clear focus on upcoming data milestones. Analyst inquiries and ongoing trials present challenges, while opportunities lie in defining patient populations and regulatory decisions post-NDA submission.

Trevi Therapeutics excels in 2024 with promising trial outcomes

Trevi Therapeutics had a strong 2024 with positive study outcomes and financial stability. Challenges include managing expenses, addressing analyst concerns, and sustaining cash burn guidance. Opportunities lie in regulatory milestones, data releases, competitive positioning, and future trial plans. Overall, Trevi's performance reflects progress in key studies and financial prudence.

Trevi Therapeutics excels in Q1 2025 trials, faces financial scrutiny

Trevi Therapeutics showed strong performance in Q1 2025 with positive trial data and regulatory progress. While facing financial challenges and analyst inquiries, the company holds opportunities for growth and collaboration. Overall, Trevi's strategic positioning and scientific advancements bode well for future development and market presence.

Trevi Therapeutics excels in Q2 2025, poised for growth

Trevi Therapeutics had a strong quarter with positive trial outcomes and substantial fundraising. While facing financial losses and expense challenges, their focus on patient needs and upcoming trials signal growth potential. Leveraging their cash reserves, Trevi is well-positioned for future developments and market expansion.

Trevi Therapeutics advances chronic cough trials, secures financial stability

Trevi Therapeutics' Q3 performance reflects progress in chronic cough trials and financial stability. While facing challenges in expense management and operational execution, the company is poised for growth. Strategic opportunities lie in expanding clinical programs and achieving key regulatory milestones.

Trevi Therapeutics excels in Q4, poised for leadership in chronic cough treatment

Trevi Therapeutics' Q4 2025 performance reflects significant advancements in chronic cough treatment and financial stability. Despite challenges in trial execution and competition, Trevi's strengths in credibility and engagement position it for growth. Opportunities in advancing trials and expanding treatment programs offer potential for Trevi to establish itself as a leader in the space.

Trevi Therapeutics advances respiratory programs with strong financial backing

Trevi Therapeutics achieved key milestones in Q1 2026, positioning themselves for significant growth in the respiratory disease market. Their strong cash position, intellectual property advancements, and planned clinical trials underscore a promising future for the company. While facing regulatory challenges and the need for continued investor support, Trevi Therapeutics remains focused on innovation and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.